Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 51 Article 4
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 51, 18 December 2008
Rapid communications
European cluster of imported falciparum malaria from Gambia
  1. Berlin Centre for Travel and Tropical Medicine, Berlin, Germany
  2. Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
  3. Helsinki University Central Hospital, Division of Infectious Diseases, Department of Medicine, Helsinki, Finland
  4. Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
  5. Hospital for Tropical Diseases and Health Protection Agency Malaria Reference Laboratory, London School of Hygiene and Tropical Medicine, United Kingdom
  6. International Health Centre, Hospital Clinic, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain
  7. Department of Infectious Disease, Section Travel Medicine, Leiden University Medical Centre, Leiden, the Netherlands
  8. Section Clinical Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany
  9. Klinik II, Centre for infectious and tropical diseases , J.W. Goethe University, Frankfurt/Main, Germany

Citation style for this article: Jelinek T, Schade Larsen C, Siikamäki H, Myrvang B, Chiodini P, Gascón J, Visser L, Kapaun A, Just-Nübling G. European cluster of imported falciparum malaria from Gambia. Euro Surveill. 2008;13(51):pii=19077. Available online:
Date of submission: 16 December 2008

A cluster of 56 patients returning  from Gambia with falciparum malaria has been noted in several countries of the European Union since September this year. TropNetEurop, the European Network on Imported Infectious Disease Surveillance, collected and reported the cases. Lack of awareness and, consequently, of prophylactic measures against malaria were apparent in the majority of patients.

On 24 November 2008, TropNetEurop, the European Network on Imported Infectious Disease Surveillance (, received information on falciparum malaria cases imported to Denmark. When this information was distributed, further notifications were received from various member sites in the following days. Apparently, the combination of lack of information about their destination and ignorance of potential malaria risks affected travellers throughout Europe.

All Danish travellers bought their journeys at the same travel agency. All stayed at the coast of Gambia at a beach close to the capital Banjul, none of them were travelling around in Gambia.

Patient 1
A man in his late fifties travelled to Gambia for two weeks and returned home in early November 2008. He did not take malaria prophylaxis. He was admitted to a local hospital ten days later with symptoms suggestive of alcohol withdrawal with tremors, difficulty walking, confusion and fever. Malaria was not suspected until family members mentioned that he had been to Gambia, and the diagnosis was first made two days after admission, when parasitaemia was 5.8%. The patient was transferred to a specialised infectious disease unit and treated for cerebral malaria with artesunate and doxycycline, sedated and put on respiratory support in the intensive care unit. The patient is still closely followed up to date, and neurological deficits still continue.

Patient 2
A woman in her fifties travelled to Gambia with a friend (patient 3) for one week in early November 2008. She did not take any malaria prophylaxis and was not vaccinated against yellow fever. Onset of symptoms was six days after her return, when she became disorientated and confused. The following days she stayed in bed with fever and headache. Fortunately, a friend visited her at the eight days later and called a doctor who admitted her to a specialised infectious disease unit. She had clinical signs of cerebral malaria and parasitaemia was 2.2%. She was treated with artesunate and doxycycline and discharged on six days after admission with no sequelae.

Patient 3
A woman in her late forties travelled to Gambia together with patient 2. She did not take any malaria prophylaxis. According to patient 2 she developed fever and diarrhoea about six days after she returned home. Ten days after her return, she was visited in her home by a general practitioner on call and was advised to see her family doctor the next day. The police was notified on the day patient 2 was admitted to hospital, but found patient 3 dead in her home. Autopsy has confirmed that she died from malaria.

Patient 4
A woman in her late forties travelled with a friend (patient 5) to the Gambia for one week in late October 2008. She did not take malaria prophylaxis. Approximately seven days after she returned home, she got diarrhoea followed by fever and headache. After four days she contacted a local hospital because she suspected she could have malaria. The diagnosis was later confirmed at a specialised infectious disease unit in Copenhagen, with falciparum malaria and <1% parasitaemia. Following treatment, the patient was discharged four days later without sequelae.

Patient 5
A woman in her late fifties travelled to Gambia with a friend (patient 4) without taking malaria prophylaxis. She developed fever 6-7 days after she returned home. However, malaria was initially not considered. Two days later she was found in the home with high fever and reduced consciousness. She was admitted on a local hospital and transferred to a department of infectious diseases. Malaria smears showed Plasmodium falciparum with 6% parasitaemia. Insufficient ventilation warranted respiratory support. The patient developed a DIC and necrosis/gangrene of eight fingers and toes.

Patient 6
A man in his late sixties travelled to Gambia for one week in November 2008 without any malaria prophylaxis. He was diagnosed with malaria seven days after his return with a parasitaemia of 5%. Following treatment he was discharged seven days later without sequelae.

Patients 7 and 8
Two brothers in their late fifties travelled together to Gambia for one week in early November 2008. They did not take malaria prophylaxis, nor were they vaccinated against yellow fever. The first brother was initially treated by his family doctor with penicillin for an upper respiratory tract infection, before he was admitted to a department of infectious diseases and diagnosed with falciparum malaria (3% parasitaemia). Then the police was contacted and a search made for the second brother. He was located in a local hospital to which he had been admitted with cerebral symptoms suggestive of alcohol withdrawal. He was transferred to the same department of infectious diseases and diagnosed with cerebral malaria (5% parasitaemia). Both brothers were treated successfully with parenteral artesunate and oral atovaquone/proguanil.

Following these initial reports from Denmark, further information from other countries was added:

Twelve cases were reported between 3 and 27 November 2008, all Finnish travellers returning from Gambia [1]. Five of these patients were female, seven were male. Age distribution was between 27 and 66 years. Their travel destinations were tourist resorts near Banjul. Nine travellers did not take any chemoprophylaxis, three used chloroquine prophylaxis. Ten of the 12 patients had received information about the malaria risk and recommended chemoprophylaxis. The duration of their stay in Gambia was between one and two weeks except for one patient who stayed four weeks. Three had complications that required treatment in intensive care, but all three recovered. For nine patients, the diagnosis was made within three days of onset of symptoms. The three patients with complications had been diagnosed with a delay of up to eight days.

Three patients were reported, two men (39 and 71 years-old), and one woman (48 years-old). None of them used chemoprophylaxis during their stay in Gambia. All three patients visited relatives and friends and stayed in and around Banjul. No complications were reported, all patients recovered.

United Kingdom
Nineteen travellers infected with falciparum malaria in Gambia were reported to the Health Protection Agency's Malaria Reference Laboratory between October and December 2008. Their age was between 21 and 62 years. Six patients were female. The majority of patients travelled as tourists (n=9), two visited friends and relatives in the country, two had migrated from Gambia to the United Kingdom (UK), and the reasons for travel of the remaining six patients were unkown. One traveller used chemoprophylaxis with proguanil, 14 took no chemoprophylaxis, and data for the remaining four were not provided.

Two patients with falciparum malaria were noted in Barcelona, Spain. Both were second generation Gambian migrants visiting relatives in Gambia for the first time. They stayed in rural areas in the country for 11 and 13 months, respectively, and did not use chemoprophylaxis. Both were male, one 14 years-old, the other 16 years-old. One of them suffered from uncomplicated malaria and recovered without complications while the other was treated in an intensive care unit due to hypotension, 9.5% parasitaemia, severe anaemia (Hb: 6.5 g/L), low platelet count: 25.000/µl, hyperbilirrubinaemia and somnolence. The infection was treated with quinine and doxycycline, and both recovered without sequelae.

The Netherlands
In the Netherlands, 10 Dutch tourists were reported with falciparum malaria after returning from Gambia between 21 September and 26 November 2008. The median age was 48 years (range 43-62), six patients were female. Three cases were related (travel companions). The median duration of stay was nine days (range 7-68). Seven travellers did not use malaria chemoprophylaxis,  two used homoeopathic drugs (chininum arsenicosum D8) and one tourist stopped atovaquone/proguanil prematurely. The median shortest incubation period was five days (range 0-18). The median interval between the first day of illness and the date of diagnosis was five days (range 0-17). Seven patients were admitted to hospital for treatment. Two patients, aged 45 and 49, died. Both patients had not used chemoprophylaxis. The time to diagnosis was 17 and six days, respectively [3].

Two patients were reported in Germany. Both were male, one 15 years-old, the other 54 years-old. They travelled to urban areas in Gambia for one and two weeks, respectively. None of them took chemoprophylaxis. Both recovered after a largely uneventful clinical course. The 54 year-old patient had been returning to Gambia for 10 years, always without prophylaxis. The 15 year-old patient was in Africa for the first time, travelling alone from Turkey, where he was borne.

During the comparatively short time period of two months and a half between September and November 2008, TropNetEurop member sites reported 56 patients returning from Gambia with falciparum malaria. Thirty-two of them were male, and 24 female. The age range was 15-71 years.

While the reasons for travel were quite diverse, a striking lack of effective prophylactic measures was apparent in all. Fourty-five patients had not used any malaria chemoprohylaxis. All seven travellers who indicated that they had taken prophylactic drugs used inadequate or downright wrong ones: two took homeopathic prophylaxis, three used chloroquine only, one used paludrine only, and one stopped taking atovaquone/proguanil too early. No data are available for the remaining four patients.
Thus, despite the documented risk of complicated falciparum malaria from Gambia, virtually all patients chose to use no or inadequate prophylaxis [2]. Several were counselled to take this decision by their travel agency, but in a few cases even by their family doctor.

The cluster underlines the necessity of competent pre-travel information and adequate protection in travellers, in particular at times when malaria appears to be decreasing but still remains a high risk for non-immune travellers [4]. Although there probably is an overuse of chemoprophylaxis against malaria among tourists travelling to Asia and Latin America, chemoprophylaxis is a must for most travellers to African destinations, and in particular to west Africa.  


  1. Valve K, Ruotsalainen E, Kärki T, Pekkanen E, Siikamäki H. Cluster of imported malaria from Gambia in Finland – travellers don’t listen to given advice. Euro Surveill. 2008;13(51):pii=19068. Available from:
  2. Williams CJ, Jones J, Chiodini P. High case-fatality from falciparum malaria in UK travellers returning from The Gambia: a case series. Travel Med Infect Dis. 2007;5(5):295-300.
  3. Data kindly provided by the Department of Epidemiology and Surveillance, Centre for Infectious Disease Control Netherlands (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  4. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford AJ, et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet. 2008;372(9649):1545-54.

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.